One such study found that venetoclax, a BCL-2 inhibitor approved for newly diagnosed AML in combination with hypomethylating agents as a less-intensive induction regimen, may mitigate the poor prognosis associated with SRSF2 mutations in AML [83]. This evidence concerns the gene SRSF2 and acute myeloid leukemia.